Surgery Websites
T32 Surgical Oncology »  Faculty Mentors »  Regulatory Sciences »  Nola Hylton, PhD
Nola Hylton, PhD

Nola Hylton, PhD

  • Professor, School of Medicine, Radiology

Contact Information

550 16th Street
San Francisco, CA 94158
Fax: 415-885-3884
Nola.Hylton@ucsf.edu
Orchid: Orchid 0000-0002-6747-1662
Open Popup
Nola Hylton, PhD, is a Professor in Residence in the Department of Radiology and Biomedical Imaging, and Director of the Breast Imaging Research Group at the University of California, San Francisco. Dr. Hylton received her BS in Chemical Engineering from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1979, and she obtained her PhD in Applied Physics from Stanford University, California in 1985.

Dr. Hylton has been integrally involved in the development of magnetic resonance imaging for the detection, diagnosis, and staging of breast cancer. Dr. Hylton is an internationally known leader in the field of breast MRI for more than 20 years. Her search has addressed the clinical optimization and evaluation of breast MRI technology. Her current research program focuses on the development and clinical evaluation of MRI techniques for characterizing breast cancers and assessing their response to treatment. Her laboratory collaborates closely with a multi-disciplinary team of radiologists, surgeons, oncologists, and science researchers nation wide. This is to optimize MRI techniques for the clinical management of breast cancer patients.

Dr. Hylton is among the first group of scholars named the Susan G. Komen for the Cure's Scientific Advisory Council. She served as co-leader for the DHHS office of Women's Health International Working Group where she identified and addressed barriers to clinical dissemination of breast MRI. She also served as the institutional Principal Investigator of the NCI International Breast MRI Consortium, which is the first large multi-center clinical trial evaluating breast MRI for breast cancer diagnosing and staging.

Dr. Hylton has over 80 published research articles, and she has written 13 book chapters and over 130 abstracts.

Expertise:
Breast Imaging

Specialty:
Breast cancer imaging, breast MRI

Professional Interests:
Breast cancer, magnetic resonance imaging, medical imaging, breast cancer detection and diagnosis, treatment assessment, optical imaging, molecular imaging, functional imaging, small animal imaging

Education and Training:
• Bachelor of Science: Massachusetts Institute of Technology (MIT), Cambridge - Chemical Engineering
• Doctor of Philosophy: Stanford University, California - Applied Physics
  Award  
  Confired By    
  Date    
  • Distinguished Investigator
  • Academy of Radiology Research
  • 2013
  • Cure Scholar Award
  • Komen
  • 2010
  • Scientific Advisory Council
  • Susan G. Komen for the Cure's
  • 2010
  • Research Scholar
  • American Cancer Society
  • 2003
  • Outstanding Contribution Award
  • American College of Radiology Imaging Network
  • 2003
  • Editor's Recognition Award with Distinction
  • Radiology
  • 1987 - 1988
  • Graduate Professional Opportunities Program Fellowship
  • Stanford University
  • 1979
  • Undergraduate Fellowship
  • Bell Telephone Laboratories
  • 1975
  • Data provided by UCSF Profiles, powered by CTSI
    ORCID iD: 0000-0002-6747-1662 Additional info
    • Real-time In Vivo MRI Biomarkers for Breast Cancer Pre-Operative Treatment Trials
      Sponsor:
      Sponsor ID:
      Funding Period:
      Apr 2008
      -
      Jun 2021
      Principal Investigator
    • Quantitative Imaging for Assessing Breast Cancer Response to Treatment
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2011
      -
      Aug 2016
      Principal Investigator
    • MRI For Staging DCIS and Assessing Response to Treatment
      Sponsor:
      Sponsor ID:
      Funding Period:
      Aug 2006
      -
      Jul 2013
      Principal Investigator
    • NMR Imaging and Spectroscopy
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jun 1993
      -
      May 2013
      Co-Investigator
    • Anatomic and Biologic Staging of Breast Disease with MRI
      Sponsor:
      Sponsor ID:
      Funding Period:
      Jan 1997
      -
      Feb 2012
      Principal Investigator
    • Mechanism-Based Evaluations of ErbB-Targeted Agents
      Sponsor:
      Sponsor ID:
      Funding Period:
      Sep 2001
      -
      Dec 2008
      Co-Investigator
    Data provided by UCSF Profiles, powered by CTSI
    MOST RECENT PUBLICATIONS FROM A TOTAL OF 179
    Data provided by UCSF Profiles, powered by CTSI
    1. Chitalia R, Pati S, Bhalerao M, Thakur SP, Jahani N, Belenky V, McDonald ES, Gibbs J, Newitt DC, Hylton NM, Kontos D, Bakas S. Expert tumor annotations and radiomics for locally advanced breast cancer in DCE-MRI for ACRIN 6657/I-SPY1. Sci Data. 2022 07 23; 9(1):440. View in PubMed
    2. Wolf DM, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher RI, Lee PRE, Zhu Z, Magbanua MJ, Sayaman R, O'Grady N, Basu A, Delson A, Coppé JP, Lu R, Braun J, I-SPY2 Investigators, Asare SM, Sit L, Matthews JB, Perlmutter J, Hylton N, Liu MC, Pohlmann P, Symmans WF, Rugo HS, Isaacs C, DeMichele AM, Yee D, Berry DA, Pusztai L, Petricoin EF, Hirst GL, Esserman LJ, van 't Veer LJ. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022 06 13; 40(6):609-623.e6. View in PubMed
    3. Le NN, Li W, Onishi N, Newitt DC, Gibbs JE, Wilmes LJ, Kornak J, Partridge SC, LeStage B, Price ER, Joe BN, Esserman LJ, Hylton NM. Effect of Inter-Reader Variability on Diffusion-Weighted MRI Apparent Diffusion Coefficient Measurements and Prediction of Pathologic Complete Response for Breast Cancer. Tomography. 2022 04 22; 8(3):1208-1220. View in PubMed
    4. Thakran S, Cohen E, Jahani N, Weinstein SP, Pantalone L, Hylton N, Newitt D, DeMichele A, Davatzikos C, Kontos D. Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Transl Oncol. 2022 Jun; 20:101411. View in PubMed
    5. Nguyen AA, Onishi N, Carmona-Bozo J, Li W, Kornak J, Newitt DC, Hylton NM. Post-Processing Bias Field Inhomogeneity Correction for Assessing Background Parenchymal Enhancement on Breast MRI as a Quantitative Marker of Treatment Response. Tomography. 2022 03 22; 8(2):891-904. View in PubMed
    6. View All Publications

     

    Site Directory
      X